{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:37:21Z","timestamp":1793266641926,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaac.2025.06.023","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:17:50Z","timestamp":1751581070000},"page":"805-817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Centanafadine for Attention-Deficit\/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4857-7397","authenticated-orcid":false,"given":"Caroline L.","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5782-7891","authenticated-orcid":false,"given":"Ann C.","family":"Childress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3111-9237","authenticated-orcid":false,"given":"Na","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8029-567X","authenticated-orcid":false,"given":"Osman","family":"Turkoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4396-2693","authenticated-orcid":false,"given":"Taisa","family":"Skubiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5749-8503","authenticated-orcid":false,"given":"Timothy E.","family":"Wilens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaac.2025.06.023_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13052-023-01456-1","article-title":"The global prevalence of ADHD in children and adolescents: a systematic review and meta-analysis","volume":"49","author":"Salari","year":"2023","journal-title":"Ital J Pediatr"},{"issue":"2","key":"10.1016\/j.jaac.2025.06.023_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"10.1016\/j.jaac.2025.06.023_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0040-1701658","article-title":"ADHD: Current concepts and treatments in children and adolescents","volume":"51","author":"Drechsler","year":"2020","journal-title":"Neuropediatrics"},{"issue":"2","key":"10.1016\/j.jaac.2025.06.023_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1060028013510699","article-title":"A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD)","volume":"48","author":"Sharma","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.jaac.2025.06.023_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1017\/S003329170500471X","article-title":"The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies","volume":"36","author":"Faraone","year":"2006","journal-title":"Psychol Med"},{"issue":"5","key":"10.1016\/j.jaac.2025.06.023_bib6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jama.292.5.619","article-title":"Attention-deficit\/hyperactivity disorder in adults","volume":"292","author":"Wilens","year":"2004","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jaac.2025.06.023_bib7","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1177\/1087054718763738","article-title":"Examining breaks and resistance in medication adherence among adolescents with ADHD as associated with school outcomes","volume":"24","author":"Barnard-Brak","year":"2020","journal-title":"J Atten Disord"},{"issue":"11","key":"10.1016\/j.jaac.2025.06.023_bib8","doi-asserted-by":"crossref","first-page":"e1459","DOI":"10.4088\/JCP.14r09478","article-title":"Examining why patients with attention-deficit\/hyperactivity disorder lack adherence to medication over the long term: a review and analysis","volume":"76","author":"Frank","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"10222","key":"10.1016\/j.jaac.2025.06.023_bib9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0140-6736(19)33004-1","article-title":"Attention-deficit hyperactivity disorder","volume":"395","author":"Posner","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jaac.2025.06.023_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180355","article-title":"The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials","volume":"12","author":"Catala-Lopez","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jaac.2025.06.023_bib11","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2023.2451","article-title":"A systematic meta-review of systematic reviews on attention deficit hyperactivity disorder","volume":"66","author":"Chaulagain","year":"2023","journal-title":"Eur Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2025.06.023_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.chc.2022.03.005","article-title":"Nonstimulant treatments for ADHD","volume":"31","author":"Newcorn","year":"2022","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.jaac.2025.06.023_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107940","article-title":"Evidence-based pharmacological treatment options for ADHD in children and adolescents","volume":"230","author":"Mechler","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jaac.2025.06.023_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0006-3223(98)00139-5","article-title":"The spectrum of behaviors influenced by serotonin","volume":"44","author":"Lucki","year":"1998","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2025.06.023_bib15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s11596-018-1912-3","article-title":"Association of serotonin receptors with attention deficit hyperactivity disorder: a systematic review and meta-analysis","volume":"38","author":"Hou","year":"2018","journal-title":"Curr Med Sci"},{"issue":"6","key":"10.1016\/j.jaac.2025.06.023_bib16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/syn.21538","article-title":"Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder","volume":"66","author":"Bymaster","year":"2012","journal-title":"Synapse"},{"issue":"2","key":"10.1016\/j.jaac.2025.06.023_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/02698811221140008","article-title":"Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: a phase 1 study in healthy male adults","volume":"37","author":"Matuskey","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jaac.2025.06.023_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/JCP.0000000000001575","article-title":"Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit\/hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials","volume":"42","author":"Adler","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jaac.2025.06.023_bib19","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2147\/NDT.S242084","article-title":"Safety and efficacy of centanafadine sustained-release in adults with attention-deficit hyperactivity disorder: results of phase 2 studies","volume":"16","author":"Wigal","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jaac.2025.06.023_bib20","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"issue":"3","key":"10.1016\/j.jaac.2025.06.023_bib21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4088\/JCP.09m05305whi","article-title":"Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)","volume":"71","author":"Sheehan","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jaac.2025.06.023_bib22","series-title":"ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch","author":"Guy","year":"1976"},{"key":"10.1016\/j.jaac.2025.06.023_bib23","series-title":"ADHD Rating Scale\u20135 for Children and Adolescents: Checklists, Norms, and Clinical Interpretation","author":"DuPaul","year":"2016"},{"issue":"2","key":"10.1016\/j.jaac.2025.06.023_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.64719\/pb.4401","article-title":"A Phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD","volume":"51","author":"Nasser","year":"2021","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"10.1016\/j.jaac.2025.06.023_bib25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/JCP.0000000000001404","article-title":"A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit\/hyperactivity disorder","volume":"41","author":"Nasser","year":"2021","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.jaac.2025.06.023_bib26","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamapediatrics.2013.465","article-title":"Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007","volume":"167","author":"Momper","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"7","key":"10.1016\/j.jaac.2025.06.023_bib27","first-page":"28","article-title":"The Clinical Global Impressions Scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.jaac.2025.06.023_bib28","author":"Conners"},{"issue":"7","key":"10.1016\/j.jaac.2025.06.023_bib29","doi-asserted-by":"crossref","DOI":"10.1176\/ajp.2007.164.7.1035","article-title":"Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA\u2019s pediatric suicidal risk analysis of antidepressants","volume":"164","author":"Posner","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2025.06.023_bib31","doi-asserted-by":"crossref","DOI":"10.1542\/pedsos.2024-000349","article-title":"Efficacy and safety of centanafadine for ADHD treatment in children: a randomized clinical trial","author":"Ward","year":"2025","journal-title":"Pediatrics Open Sci"},{"issue":"6","key":"10.1016\/j.jaac.2025.06.023_bib32","first-page":"528","article-title":"Assessment of centanafadine in adults with attention-deficit\/hyperactivity disorder: a matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release","volume":"30","author":"Schein","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"10.1016\/j.jaac.2025.06.023_bib33","article-title":"Treatments for ADHD in children and adolescents: a systematic review","volume":"153","author":"Peterson","year":"2024","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.jaac.2025.06.023_bib34","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2025.06.023_bib35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40272-021-00470-2","article-title":"Executive function outcome of treatment with viloxazine extended-release capsules in children and adolescents with attention-deficit\/hyperactivity disorder: a post-hoc analysis of four randomized clinical trials","volume":"23","author":"Faraone","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"12","key":"10.1016\/j.jaac.2025.06.023_bib36","first-page":"678","article-title":"Using meta-analysis to compare the efficacy of medications for attention-deficit\/hyperactivity disorder in youths","volume":"34","author":"Faraone","year":"2009","journal-title":"P T"},{"key":"10.1016\/j.jaac.2025.06.023_bib37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neubiorev.2018.02.001","article-title":"The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit\/hyperactivity disorder and other psychiatric comorbidities","volume":"87","author":"Faraone","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"10.1016\/j.jaac.2025.06.023_bib38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s44192-022-00030-1","article-title":"An overview on neurobiology and therapeutics of attention-deficit\/hyperactivity disorder","volume":"3","author":"da Silva","year":"2023","journal-title":"Discov Ment Health"},{"key":"10.1016\/j.jaac.2025.06.023_bib39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuint.2015.02.001","article-title":"Does serotonin deficit mediate susceptibility to ADHD?","volume":"82","author":"Banerjee","year":"2015","journal-title":"Neurochem Int"},{"issue":"6","key":"10.1016\/j.jaac.2025.06.023_bib40","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s10571-021-01064-9","article-title":"The roles of serotonin in neuropsychiatric disorders","volume":"42","author":"Pourhamzeh","year":"2022","journal-title":"Cell Mol Neurobiol"}],"updated-by":[{"DOI":"10.1016\/j.jaac.2026.06.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000}},{"DOI":"10.1016\/j.jaac.2026.06.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000}}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856725003272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856725003272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T01:39:17Z","timestamp":1779845957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856725003272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0890856725003272"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2025.06.023","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Centanafadine for Attention-Deficit\/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2025.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92025 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}